| IL-2 therapy | Clinical trial | |||||||
|---|---|---|---|---|---|---|---|---|
| Type | Agent (company) | Description | Delivery route | Indication | Co-therapy | Phase | Status | References |
| Immunocytokine | AMG-592/efavaleukin-alpha (Amgen) | Fc–IL-2 mutein fusion protein | s.c. | SLE | – | 1/2 | Recruiting | NCT03451422 (Tchao et al., 2017) |
| s.c. | RA | – | 1/2 | Recruiting | NCT03410056 (Tchao et al., 2017) | |||
| s.c. | Chronic GvHD | – | 1/2 | Recruiting | NCT03422627 (Tchao et al., 2017) | |||
| PEGylated IL-2 | NKTR-358 (Nektar Therapeutics) | PEG–IL-2 with IL-2Rα bias > IL-2Rβ bias | i.v. | SLE | – | 1 | Recruiting | NCT03556007 |
| IL-2 therapy | Clinical trial | |||||||
|---|---|---|---|---|---|---|---|---|
| Type | Agent (company) | Description | Delivery route | Indication | Co-therapy | Phase | Status | References |
| Immunocytokine | AMG-592/efavaleukin-alpha (Amgen) | Fc–IL-2 mutein fusion protein | s.c. | SLE | – | 1/2 | Recruiting | NCT03451422 ( |
| s.c. | RA | – | 1/2 | Recruiting | NCT03410056 ( | |||
| s.c. | Chronic GvHD | – | 1/2 | Recruiting | NCT03422627 ( | |||
| PEGylated IL-2 | NKTR-358 (Nektar Therapeutics) | PEG–IL-2 with IL-2Rα bias > IL-2Rβ bias | i.v. | SLE | – | 1 | Recruiting | NCT03556007 |
RA, rheumatoid arthritis.